Fertility Preservation
Conditions
Brief summary
Whether it is for oncology or personal reasons, fertility preservation allows participants to preserve their oocytes (eggs) at their current age and condition for a better chance of having a baby in the future. In order to proceed with fertility preservation, participants will need to undergo in vitro fertilization (IVF), which is standard practice, and take stimulation medication to stimulate production of more follicles. The combination of both Rekovelle and Menopur for fertility preservation may increase ovarian response to stimulation and increase the number of oocytes retrieved to give better chances of embryos once the oocytes will be fertilized. The goal in this study is to understand the effect of oxydative stress on the quality of oocytes. For the purpose of the study and to evaluate this connection, serum levels of oxidative stress and cf-DNA in your blood will be measured. Oocyte quality will also be assessed with Magenta, a prediction tool utilizing artificial intelligence (AI). This method is non-invasive and has no risks on the oocytes.
Interventions
OTHEROxidative stress
Oxidative stress occurs as soon as there is an imbalance between pro- / antioxidants, and molecules exhibiting antioxidant properties are at the forefront of fertility treatment and preservation. Oxidated stress will be measured by blood sample
OTHERcf-DNA
cfDNA, extracted from blood plasma in samples collected will uncover the potential role of cfDNA as a stress signal released in response to oxidative stress
OTHERMAGENTA AI
Non-invasive technique analyzing images of oocytes that can differentiate oocytes with a higher reproductive potential reflective of their quality
Sponsors
Ferring Pharmaceuticals
Clinique Ovo
Study design
Allocation
NON_RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 37 Years
Healthy volunteers
No
Inclusion criteria
\- Women 18 to 37 years of age inclusively eligible for fertility preservation for either social or oncology reason
Exclusion criteria
* Pregnancy and lactation * Uncontrolled thyroid or adrenal dysfunction * Tumours of the hypothalamus or pituitary gland * Ovarian enlargement not due to polycystic ovarian syndrome * Gynaecological haemorrhages of unknown aetiology * Endometriosis stage III/IV * Use of hormonal preparations (except for thyroid medication) during the last menstrual cycle * Use of Coenzyme Q10 during the stimulation cycle * Renal and/or hepatic impairment * Hypersensitivity to any active ingredient or excipients in follitropin delta and/or HP-hMG
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Evaluate the correlation between the oxidative stress and the quality of oocytes | Change from baseline oxidative stress at the end of IVF controlled ovarian stimulaition | Serum sample measure variations of oxidation-reduction potential (ORP) with MiOXSYS analyzer and by PCR |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Evaluation of oocyte quality by visualization | At the end of IVF stimulation | Oocyte quality will be measured by MAGENTA AI |
| Assessment of good quality oocytes | IVF stimulation cycle | Measurement of serum estradiol levels |
| Number of mature oocytes retrieved | IVF stimulation cycle | Efficacy of the combination or Rekovelle and Menopur |
Countries
Canada
Outcome results
None listed